Hereditary pulmonary alveolar proteinosis (hPAP) is a rare interstitial lung disease caused by mutation in CSF2RA/CSF2RB, characterized by the deposition of pulmonary surfactant due to the alveolar macrophage dysfunction. The whole lung lavage can effectively alleviate the symptoms but is associated with potential complications. Cell therapy is a novel approach with advances that provide a new therapeutic strategy for the treatment of hPAP.
Keyphrases
- cell therapy
- interstitial lung disease
- pulmonary hypertension
- systemic sclerosis
- stem cells
- mesenchymal stem cells
- rheumatoid arthritis
- idiopathic pulmonary fibrosis
- adipose tissue
- oxidative stress
- cerebrospinal fluid
- sleep quality
- combination therapy
- systemic lupus erythematosus
- climate change
- disease activity
- risk assessment
- replacement therapy